GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AVANIR Pharmaceuticals (FRA:AV2B) » Definitions » 5-Year Yield-on-Cost %

AVANIR Pharmaceuticals (FRA:AV2B) 5-Year Yield-on-Cost % : 0.00 (As of May. 17, 2024)


View and export this data going back to . Start your Free Trial

What is AVANIR Pharmaceuticals 5-Year Yield-on-Cost %?

AVANIR Pharmaceuticals's yield on cost for the quarter that ended in Sep. 2014 was 0.00.


The historical rank and industry rank for AVANIR Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:



FRA:AV2B's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.08
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of AVANIR Pharmaceuticals's 5-Year Yield-on-Cost %

For the Drug Manufacturers - Specialty & Generic subindustry, AVANIR Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVANIR Pharmaceuticals's 5-Year Yield-on-Cost % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AVANIR Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where AVANIR Pharmaceuticals's 5-Year Yield-on-Cost % falls into.



AVANIR Pharmaceuticals 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of AVANIR Pharmaceuticals is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

AVANIR Pharmaceuticals  (FRA:AV2B) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


AVANIR Pharmaceuticals 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


AVANIR Pharmaceuticals (FRA:AV2B) Business Description

Traded in Other Exchanges
N/A
Address
Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.

AVANIR Pharmaceuticals (FRA:AV2B) Headlines

No Headlines